Memantine in dementia: a review of the current evidence

Bibliography

• Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;69(3):341-8
   PubMedGoogle Scholar
• Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3(3):186-91
   PubMedGoogle Scholar
• Ferri CP, Prince M, Brayne C, Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-17
   PubMedGoogle Scholar
• Herrmann N, Tam DY, Balshaw R, The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada. Can J Psychiatry 2010;55(12):768-75
   PubMedGoogle Scholar
• Hux MJ, O'Brien BJ, Iskedjian M, Relation between severity of Alzheimer's disease and costs of caring. Cmaj 1998;159(5):457-65
   PubMedGoogle Scholar
• Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int J Geriatr Psychiatry 1999;14(1):3-47
   PubMedGoogle Scholar
• Greenamyre JT. The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 1986;43(10):1058-63
   PubMedGoogle Scholar
• Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989;10(5):593-602
   PubMedGoogle Scholar
• Kornhuber J, Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41(2):135-44
   PubMedGoogle Scholar
• Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998;116:331-47
   PubMed Web of Science ®Google Scholar
• Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 1998;11(9):523-69
   PubMedGoogle Scholar
• Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol 1957;58(2):193-201
   PubMedGoogle Scholar
• Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164(880):719-21
   PubMedGoogle Scholar
• Olney JW, Sharpe LG. Brain lesions in an infant rhesus monkey treated with monsodium glutamate. Science 1969;166(903):386-8
   PubMedGoogle Scholar
• Olney JW, Sharpe LG, Feigin RD. Glutamate-induced brain damage in infant primates. J Neuropathol Exp Neurol 1972;31(3):464-88
   PubMedGoogle Scholar
• Bleich S, Romer K, Wiltfang J, Kornhuber J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18(Suppl 1):S33-40
   PubMedGoogle Scholar
• Danysz W, Parsons CG, Mobius HJ, Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease–a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res 2000;2(2-3):85-97
   PubMedGoogle Scholar
• Li L, Sengupta A, Haque N, Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 2004;566(1-3):261-9
   PubMedGoogle Scholar
• Wu TY, Chen CP. Dual action of memantine in Alzheimer disease: a hypothesis. Taiwan J Obstet Gynecol 2009;48(3):273-7
   PubMedGoogle Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83(13):4913-17
   PubMed Web of Science ®Google Scholar
• Lee HG, Perry G, Moreira PI, Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005;11(4):164-9
   PubMedGoogle Scholar
• Martinez-Coria H, Green KN, Billings LM, Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 2010;176(2):870-80
   PubMedGoogle Scholar
• Ray B, Banerjee PK, Greig NH, Lahiri DK. Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett 2010;470(1):1-5
   PubMedGoogle Scholar
• European Medicines Agency. Ebixa (memantine) 2009. 24 June 2010. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000463/human_med_000750.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Cited 21 August 2010]
   Google Scholar
• FDA approves memantine drug for treating AD. Am J Alzheimers Dis Other Demen 2003;18(6):329-30
   Google Scholar
• Fischer PA, Jacobi P, Schneider E, Schonberger B. Effects of intravenous administration of memantine in parkinsonian patients (author's transl). Arzneimittelforschung 1977;27(7):1487-9
   PubMedGoogle Scholar
• Schneider E, Fischer PA, Clemens R, Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study. Dtsch Med Wochenschr 1984;109(25):987-90
   PubMedGoogle Scholar
• Miltner FO. Valve of symptomatic therapy with memantine in cerebral coma. I. Correlation with coma stages and EEG spectral patterns. Arzneimittelforschung 1982;32(10):1268-70
   PubMedGoogle Scholar
• Miltner FO. Valve of symptomatic therapy with memantine in cerebral coma. II. Development of stretch synergisms in coma with brain stem symptoms. Arzneimittelforschung 1982;32(10):1271-3
   PubMedGoogle Scholar
• Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsychopharmacol Biol Psychiatry 1986;10(1):87-93
   PubMedGoogle Scholar
• McKeage K. Spotlight on memantine in moderate to severe Alzheimer's disease. Drugs Aging 2010;27(2):177-9
   PubMedGoogle Scholar
• Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine: an update. Curr Neuropharmacol 2008;6(1):55-78
   PubMedGoogle Scholar
• European Medicines Agency. Axura (memantine) 2009. 13 August 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000378/WC500029678.pdf [Cited 16 November 2010]
   Google Scholar
• Lundbeck Canada. Ebixa Product Monograph 2009. 18 May 2010. Available from: http://www.ebixa.com/content/downloadarea/pdf/monograph.pdf [Cited 16 September 2010]
   Google Scholar
• Wesemann W, Sturm G, Funfgeld EW. Distribution of metabolism of the potential anti-parkinson drug memantine in the human. J Neural Transm Suppl 1980;16:143-8
   Google Scholar
• Micuda S, Mundlova L, Anzenbacherova E, Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur J Clin Pharmacol 2004;60(8):583-9
   PubMedGoogle Scholar
• Periclou AP, Ventura D, Sherman T, Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother 2004;38(9):1389-94
   PubMedGoogle Scholar
• Wenk GL, Quack G, Moebius HJ, Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci 2000;66(12):1079-83
   PubMedGoogle Scholar
• Moellentin D, Picone C, Leadbetter E. Memantine-induced myoclonus and delirium exacerbated by trimethoprim. Ann Pharmacother 2008;42(3):443-7
   PubMedGoogle Scholar
• Monastero R, Camarda C, Pipia C, Camarda R. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007;78(5):546
   PubMedGoogle Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14(2):135-46
   PubMedGoogle Scholar
• Reisberg B, Doody R, Stoffler A, Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348(14):1333-41
   PubMedGoogle Scholar
• Reisberg B, Doody R, Stoffler A, A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63(1):49-54
   PubMedGoogle Scholar
• Rive B, Vercelletto M, Damier FD, Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19(5):458-64
   PubMedGoogle Scholar
• Kurz X, Scuvee-Moreau J, Rive B, Dresse A. A new approach to the qualitative evaluation of functional disability in dementia. Int J Geriatr Psychiatry 2003;18(11):1050-5
   PubMedGoogle Scholar
• van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord 2007;21(2):136-43
   PubMedGoogle Scholar
• Doody R, Wirth Y, Schmitt F, Mobius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2004;18(2):227-32
   PubMedGoogle Scholar
• Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 2004;19(10):919-25
   PubMedGoogle Scholar
• Lanctot KL, Herrmann N, Yau KK, Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Cmaj 2003;169(6):557-64
   PubMedGoogle Scholar
• Calabrese P, Essner U, Forstl H. Memantine (Ebixa) in clinical practice - results of an observational study. Dement Geriatr Cogn Disord 2007;24(2):111-17
   PubMedGoogle Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004;291(3):317-24
   PubMed Web of Science ®Google Scholar
• Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006;20(4):263-8
   PubMedGoogle Scholar
• van Dyck CH, Schmitt FA, Olin JT. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006;14(5):428-37
   PubMedGoogle Scholar
• Dantoine T, Auriacombe S, Sarazin M, Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006;60(1):110-18
   PubMedGoogle Scholar
• Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008;22(3):209-21
   PubMedGoogle Scholar
• Winblad B, Jones RW, Wirth Y, Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007;24(1):20-7
   PubMedGoogle Scholar
• Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2007;24(2):138-45
   PubMedGoogle Scholar
• Ferris S, Ihl R, Robert P, Treatment effects of memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement 2009;5(5):369-74
   PubMedGoogle Scholar
• Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. J Alzheimers Dis 2008;14(2):193-9
   PubMedGoogle Scholar
• Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 2009;24(5):532-8
   PubMedGoogle Scholar
• Clerici F, Vanacore N, Elia A, Memantine in moderately-severe-to-severe Alzheimer's disease: a postmarketing surveillance study. Drugs Aging 2009;26(4):321-32
   PubMedGoogle Scholar
• McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;2:CD003154
   PubMedGoogle Scholar
• Peskind ER, Potkin SG, Pomara N, Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14(8):704-15
   PubMedGoogle Scholar
• Ott BR, Blake LM, Kagan E, Resnick M. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol 2007;254(3):351-8
   PubMedGoogle Scholar
• Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2007;11(4):471-9
   PubMedGoogle Scholar
• Kubova Z, Kremlacek J, Valis M, Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli. J Clin Neurophysiol 2010;27(5):334-40
   PubMedGoogle Scholar
• Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5(1):83-9
   PubMedGoogle Scholar
• Olin JT, Bhatnagar V, Reyes P, Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry 2010;25(4):419-26
   PubMedGoogle Scholar
• Modrego PJ, Fayed N, Errea JM, Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol 2010;17(3):405-12
   PubMedGoogle Scholar
• Jones RW, Bayer A, Inglis F, Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22(3):258-62
   PubMedGoogle Scholar
• Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 2008;31(7):577-85
   PubMedGoogle Scholar
• Rammes G, Rupprecht R, Ferrari U, The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001;306(1-2):81-4
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77
   PubMed Web of Science ®Google Scholar
• Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67(1):57-63
   PubMedGoogle Scholar
• Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005;20(5):459-64
   PubMedGoogle Scholar
• Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23(5):537-45
   PubMedGoogle Scholar
• Herrmann N, Cappell J, Eryavec GM, Lanctot KL. Changes in nursing burden following memantine for agitation and aggression in long term care residents with moderate to severe Alzheimer's disease: an open-Label pilot study. CNS Drugs (In press)
   Google Scholar
• Schmidt R, Baumhackl U, Berek K, Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria. Neuropsychiatr 2008;24(2):125-31
   Google Scholar
• Cappell J, Herrmann N, Cornish S, Lanctot KL. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010;24(11):909-27
   PubMedGoogle Scholar
• Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease. Pharmacoeconomics 2005;23(2):193-206
   PubMedGoogle Scholar
• Antonanzas F, Rive B, Badenas JM, Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain. Eur J Health Econ 2006;7(2):137-44
   PubMedGoogle Scholar
• Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a markov model in Finland. Clin Drug Investig 2004;24(7):373-84
   PubMedGoogle Scholar
• Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry 2007;52(8):519-26
   PubMedGoogle Scholar
• Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic markov model from a UK perspective. Drugs Aging 2004;21(9):607-20
   PubMedGoogle Scholar
• Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 2005;3(2):77-86
   PubMedGoogle Scholar
• Rive B, Grishchenko M, Guilhaume-Goulant C, Cost effectiveness of memantine in Alzheimer's disease in the UK. J Med Econ 2010;13(2):371-80
   PubMedGoogle Scholar
• Lopez OL, Becker JT, Wahed AS, Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80(6):600-7
   PubMedGoogle Scholar
• Wimo A, Winblad B, Stoffler A, Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21(5):327-40
   PubMedGoogle Scholar
• Orgogozo JM, Rigaud AS, Stoffler A, Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33(7):1834-9
   PubMedGoogle Scholar
• Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17(6):297-305
   PubMedGoogle Scholar
• Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005;65(3):481-2
   PubMedGoogle Scholar
• Huey ED, Dustin IH, Overman GP, Development of subtle psychotic symptoms with memantine: a case report. J Clin Psychiatry 2005;66(5):658-9
   PubMedGoogle Scholar
• Aarsland D, Ballard C, Walker Z, Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613-18
   PubMedGoogle Scholar
• Diehl-Schmid J, Forstl H, Perneczky R, A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008;23(7):754-9
   PubMedGoogle Scholar